| Bioactivity | Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer[1][2]. |
| Invitro | Ensituximab (NPC-1C) 是一种嵌合 IgG1 单克隆抗体，在结合其靶标后促进抗体依赖性细胞的细胞毒性，MUC5AC 是一种肿瘤特异性变体，一种由结直肠癌 (CRC) 和胰腺癌特异性表达的抗原[1]。 |
| Name | Ensituximab |
| CAS | 1092658-06-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564. [2]. Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11(1):8. |